Published in Cell on July 27, 2017
Crystal structure of rhodopsin: A G protein-coupled receptor. Science (2000) 28.60
ZINC--a free database of commercially available compounds for virtual screening. J Chem Inf Model (2005) 16.75
Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature (2011) 13.92
The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol (2003) 9.99
Transduction of receptor signals by beta-arrestins. Science (2005) 9.87
Predicting new molecular targets for known drugs. Nature (2009) 9.71
Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature (2011) 9.61
Thrombin signalling and protease-activated receptors. Nature (2000) 9.27
Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature (1997) 7.92
Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science (1999) 7.57
Diversity of G proteins in signal transduction. Science (1991) 7.41
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
The antagonism of acetyl choline by atropine. J Physiol (1926) 6.99
Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci (1983) 6.89
Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature (2000) 6.58
Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science (1996) 6.50
Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature (1996) 6.32
A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem (1980) 6.06
Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science (2010) 5.86
The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem (2002) 5.53
Teratogen-mediated inhibition of target tissue response to Shh signaling. Science (1998) 5.28
Molecular signatures of G-protein-coupled receptors. Nature (2013) 5.19
Protein kinase inhibitors: insights into drug design from structure. Science (2004) 4.86
Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature (2011) 4.60
beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science (1990) 4.53
A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem (1993) 4.52
Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci (2007) 4.35
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A (2002) 4.34
Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov (2004) 4.31
The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol (2015) 4.28
Temporally precise in vivo control of intracellular signalling. Nature (2009) 4.14
Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature (1997) 4.12
Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol (2012) 3.83
Trends in the exploitation of novel drug targets. Nat Rev Drug Discov (2011) 3.60
Drugs and valvular heart disease. N Engl J Med (2007) 3.41
Structural basis for allosteric regulation of GPCRs by sodium ions. Science (2012) 3.40
Structure of the agonist-bound neurotensin receptor. Nature (2012) 3.23
Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol (2001) 3.11
Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science (2012) 3.07
3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med (2004) 2.96
Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature (2013) 2.87
Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest (2000) 2.78
Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J Am Chem Soc (2010) 2.62
Structural features for functional selectivity at serotonin receptors. Science (2013) 2.60
Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature (2013) 2.49
Structure-based discovery of beta2-adrenergic receptor ligands. Proc Natl Acad Sci U S A (2009) 2.48
Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc Natl Acad Sci U S A (2011) 2.44
Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. Nature (2015) 2.43
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation (2000) 2.41
Prescription drug spending trends in the United States: looking beyond the turning point. Health Aff (Millwood) (2008) 2.37
Opiate agonists and antagonists discriminated by receptor binding in brain. Science (1973) 2.27
Beta-adrenergic receptor kinase: primary structure delineates a multigene family. Science (1989) 2.24
Molecular control of δ-opioid receptor signalling. Nature (2014) 2.22
Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol (1994) 2.22
Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol (2011) 2.10
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A (2011) 1.98
A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci (2011) 1.93
Heterotrimeric G proteins precouple with G protein-coupled receptors in living cells. Proc Natl Acad Sci U S A (2005) 1.91
Structural basis for molecular recognition at serotonin receptors. Science (2013) 1.86
Structure-based discovery of opioid analgesics with reduced side effects. Nature (2016) 1.79
The mammalian beta 2-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system. Biochemistry (1984) 1.77
Structural insights into µ-opioid receptor activation. Nature (2015) 1.77
Structural Insights into the Dynamic Process of β2-Adrenergic Receptor Signaling. Cell (2015) 1.68
Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody. Nature (2013) 1.68
Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65. Nature (2015) 1.66
Extra-helical binding site of a glucagon receptor antagonist. Nature (2016) 1.65
A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther (2013) 1.62
Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev Pharmacol Toxicol (2011) 1.61
Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design. J Med Chem (2012) 1.60
Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc Natl Acad Sci U S A (2012) 1.57
Phase-plate cryo-EM structure of a class B GPCR-G-protein complex. Nature (2017) 1.55
Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation. Nature (2016) 1.55
Mutations in the V2 vasopressin receptor gene are associated with X-linked nephrogenic diabetes insipidus. Nat Genet (1992) 1.54
DREADDs for Neuroscientists. Neuron (2016) 1.52
Crystal Structure of the Human Cannabinoid Receptor CB1. Cell (2016) 1.50
In silico design of novel probes for the atypical opioid receptor MRGPRX2. Nat Chem Biol (2017) 1.45
Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. Annu Rev Pharmacol Toxicol (2007) 1.42
Allosteric sodium in class A GPCR signaling. Trends Biochem Sci (2014) 1.41
Orphan receptor ligand discovery by pickpocketing pharmacological neighbors. Nat Chem Biol (2016) 1.41
Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. J Med Chem (2009) 1.37
International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors. Pharmacol Rev (2015) 1.29
New insights from structural biology into the druggability of G protein-coupled receptors. Trends Pharmacol Sci (2012) 1.26
Two disparate ligand-binding sites in the human P2Y1 receptor. Nature (2015) 1.25
Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor. J Med Chem (2004) 1.23
Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ Res (2011) 1.19
GPCR-G Protein-β-Arrestin Super-Complex Mediates Sustained G Protein Signaling. Cell (2016) 1.18
Activation of the inhibitory GTP-binding protein of adenylate cyclase, Gi, by beta-adrenergic receptors in reconstituted phospholipid vesicles. J Biol Chem (1984) 1.12
Intracellular allosteric antagonism of the CCR9 receptor. Nature (2016) 1.08
The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. J Pharmacol Exp Ther (2014) 1.05
Comprehensive characterization of the Published Kinase Inhibitor Set. Nat Biotechnol (2015) 1.00
Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily. J Biol Chem (2015) 1.00
The role of kinetic context in apparent biased agonism at GPCRs. Nat Commun (2016) 0.98
Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature (2017) 0.97
International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. Pharmacol Rev (2014) 0.96
Endogenous allosteric modulators of G protein-coupled receptors. J Pharmacol Exp Ther (2015) 0.90
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet (2016) 0.88
Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). J Med Chem (2015) 0.87
From heptahelical bundle to hits from the Haystack: structure-based virtual screening for GPCR ligands. Methods Enzymol (2013) 0.86
NMR structure and dynamics of the agonist dynorphin peptide bound to the human kappa opioid receptor. Proc Natl Acad Sci U S A (2015) 0.85